(The Hill) — Pfizer on Tuesday announced its maternal vaccine for RSV, administered during pregnancy, was effective at preventing infants from developing severe symptoms from birth through their first ...

Please provide your email address to receive an email when new articles are posted on . RSVpreF had a vaccine effectiveness of 92% for patients aged 60 years or older. Effectiveness remained at 90% or ...

The largest study of respiratory syncytial virus (RSV) infection outcomes in people with systemic autoimmune rheumatic diseases (SARDs) to date found that more than half were hospitalized with the ...

A U.K. marketing watchdog has sanctioned Sanofi after ruling its CEO Paul Hudson may have undermined the U.K. government’s vaccine program by making “bold claims” about a procurement choice. Pfizer ...

Please provide your email address to receive an email when new articles are posted on . Researchers compared pregnancy risks and birth outcomes between vaccinated and unvaccinated pregnant women. They ...

In this self-controlled case series, myocardial infarction rates were nearly 9 times greater in the week after an RSV-related hospitalization compared with a control period prior to infection. Stroke ...

The Food and Drug Administration's independent advisors on Tuesday recommended what would be the world's first RSV vaccine, a shot from Pfizer for adults ages 60 and older, despite safety concerns ...